Maturity onset diabetes of the young and fibrin-related thrombosis risk.
Adult
Biomarkers
/ blood
C-Reactive Protein
/ analysis
Complement C3
/ analysis
Diabetes Mellitus, Type 2
/ blood
Female
Fibrin
/ analysis
Genetic Predisposition to Disease
Hepatocyte Nuclear Factor 1-alpha
/ genetics
Humans
Male
Middle Aged
Pilot Projects
Plasminogen Activator Inhibitor 1
/ blood
Risk Factors
Thrombosis
/ blood
Young Adult
MODY
clot structure
fibrinolysis
thrombosis
Journal
Diabetes & vascular disease research
ISSN: 1752-8984
Titre abrégé: Diab Vasc Dis Res
Pays: England
ID NLM: 101234011
Informations de publication
Date de publication:
Historique:
entrez:
18
12
2020
pubmed:
19
12
2020
medline:
26
1
2021
Statut:
ppublish
Résumé
Fibrin network characteristics determine predisposition to cardiovascular disease (CVD). Individuals with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) have higher risk of CVD and display deranged fibrin network structure. Those with maturity onset diabetes of the young (MODY) may also be at increased risk but their fibrin clot properties have not been studied. Plasma clots properties from 13 individuals with HNF1A-MODY, 12 matched-individuals with T2DM and 12 with T1DM were studied using a validated turbidimetric assay and confocal microscopy. Plasma levels of fibrinogen, plasminogen activator inhibitor-1, complement C3 and C-reactive protein were also measured. MODY clot maximum absorbance was 0.37 ± 0.03 AU, similar to T1DM (0.32 ± 0.03 AU; HNF1A-MODY fibrin network alterations are at least as pronounced as in T1DM but less thrombotic than T2DM clots. Differences in fibrin clot characteristics comparing HNF1A-MODY and T2DM may, in part, relate to lower C3 levels.
Sections du résumé
BACKGROUND
Fibrin network characteristics determine predisposition to cardiovascular disease (CVD). Individuals with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) have higher risk of CVD and display deranged fibrin network structure. Those with maturity onset diabetes of the young (MODY) may also be at increased risk but their fibrin clot properties have not been studied.
METHODS
Plasma clots properties from 13 individuals with HNF1A-MODY, 12 matched-individuals with T2DM and 12 with T1DM were studied using a validated turbidimetric assay and confocal microscopy. Plasma levels of fibrinogen, plasminogen activator inhibitor-1, complement C3 and C-reactive protein were also measured.
RESULTS
MODY clot maximum absorbance was 0.37 ± 0.03 AU, similar to T1DM (0.32 ± 0.03 AU;
CONCLUSIONS
HNF1A-MODY fibrin network alterations are at least as pronounced as in T1DM but less thrombotic than T2DM clots. Differences in fibrin clot characteristics comparing HNF1A-MODY and T2DM may, in part, relate to lower C3 levels.
Identifiants
pubmed: 33334146
doi: 10.1177/1479164120963048
pmc: PMC7919224
doi:
Substances chimiques
Biomarkers
0
C3 protein, human
0
Complement C3
0
HNF1A protein, human
0
Hepatocyte Nuclear Factor 1-alpha
0
Plasminogen Activator Inhibitor 1
0
SERPINE1 protein, human
0
Fibrin
9001-31-4
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1479164120963048Subventions
Organisme : British Heart Foundation
ID : FS/19/45/34443
Pays : United Kingdom
Références
Diab Vasc Dis Res. 2012 Jul;9(3):216-25
pubmed: 22253322
Clin Med (Lond). 2013 Jun;13(3):278-81
pubmed: 23760703
Diabetologia. 1998 Apr;41(4):467-73
pubmed: 9562352
Diabetologia. 2012 Apr;55(4):1103-13
pubmed: 21918806
Diabetes Care. 2014 Oct;37(10):2843-63
pubmed: 25114297
Diabet Med. 2009 Feb;26(2):142-8
pubmed: 19236616
J Clin Endocrinol Metab. 2012 May;97(5):1463-73
pubmed: 22378816
Diabetologia. 2010 Dec;53(12):2504-8
pubmed: 20499044
J Exp Med. 2001 Dec 3;194(11):1683-9
pubmed: 11733582
Diabetologia. 2014 Aug;57(8):1737-41
pubmed: 24838681
JAMA. 2014 Jan 15;311(3):279-86
pubmed: 24430320
J Clin Endocrinol Metab. 2012 Dec;97(12):E2282-7
pubmed: 22996148
Thromb Haemost. 2020 Mar;120(3):412-422
pubmed: 31975352
Diabetologia. 2005 Dec;48(12):2519-24
pubmed: 16247597
Thromb Haemost. 2020 Jan;120(1):75-82
pubmed: 31733633
Diabet Med. 2016 Jul;33(7):976-84
pubmed: 26479152
Diabetes Care. 2006 Apr;29(4):798-804
pubmed: 16567818